 |
|
Safety of Newly Approved Drugs
Implications for Prescribing
Robert J. Temple, MD;
Martin H. Himmel, MD,MPH
JAMA. 2002;287:2273-2275.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In this issue of THE JOURNAL, Lasser and colleagues1 examine the timing and nature of the black box warnings added to labeling, as reflected in the Physicians' Desk Reference, and of removal of drugs from the market to address the question of whether clinicians should hesitate to prescribe new drugs that may have unrecognized adverse drug reactions (ADRs). Premarketing trials in a few thousand (usually relatively uncomplicated) patients do not detect all of a drug's adverse effects, especially relatively rare ones. Frequent postmarketing labeling changes are therefore inevitable and should be anticipated. Sometimes the new information is so important it fundamentally changes the place of the drug in therapy (eg, leads to second-line status) and sometimes the postmarketing discoveries cause the drug to be withdrawn.
Examining the appearance of black box warnings and withdrawals is a reasonable way to seek out . . . [Full Text of this Article]
Author Affiliations: Center for Drug Evaluation and Research Policy, Food and Drug Administration, Rockville, Md.
RELATED LETTER
Postmarketing Surveillance and Black Box Warnings
Garth K. Graham, Anthony K. Wutoh, Rita D. Wutoh, J. P. Hampson, J. N. Harvey, Stephen A. Goldman, Penelope J. Greene, Theodore J. La Vaque, Karen E. Lasser, Steffie J. Woolhandler, David U. Himmelstein, Sidney M. Wolfe, Robert J. Temple, and Martin H. Himmel
JAMA. 2002;288(8):955-959.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Timing of New Black Box Warnings and Withdrawals for Prescription Medications
Karen E. Lasser, Paul D. Allen, Steffie J. Woolhandler, David U. Himmelstein, Sidney M. Wolfe, and David H. Bor
JAMA. 2002;287(17):2215-2220.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Role of CYP2E1 Immunoglobulin G4 Subclass Antibodies and Complement in Pathogenesis of Idiosyncratic Drug-Induced Hepatitis
Njoku et al.
CVI 2006;13:258-265.
ABSTRACT
| FULL TEXT
A Search to Predict Potential for Drug-Induced Cardiovascular Toxicity
Hamlin
Toxicol Pathol 2006;34:75-80.
ABSTRACT
| FULL TEXT
Utility of Nutraceutical Products Marketed for Cognitive and Memory Enhancement
McDougall et al.
J Holist Nurs 2005;23:415-433.
ABSTRACT
Adverse Drug Event Surveillance and Drug Withdrawals in the United States, 1969-2002: The Importance of Reporting Suspected Reactions
Wysowski and Swartz
Arch Intern Med 2005;165:1363-1369.
ABSTRACT
| FULL TEXT
The Research on Adverse Drug Events and Reports (RADAR) Project
Bennett et al.
JAMA 2005;293:2131-2140.
ABSTRACT
| FULL TEXT
Today's FDA
Slater
NEJM 2005;352:293-297.
FULL TEXT
Recognizing Drug-Induced Liver Injury: Current Problems, Possible Solutions
Lee and Senior
Toxicol Pathol 2005;33:155-164.
ABSTRACT
| FULL TEXT
Drug-Induced Prolongation of the QT Interval
Roden
NEJM 2004;350:1013-1022.
FULL TEXT
Dissemination of Information on Potentially Fatal Adverse Drug Reactions for Cancer Drugs From 2000 to 2002: First Results From the Research on Adverse Drug Events and Reports Project
Ladewski et al.
JCO 2003;21:3859-3866.
ABSTRACT
| FULL TEXT
Postmarketing Surveillance and Black Box Warnings
Graham et al.
JAMA 2002;288:955-959.
FULL TEXT
Market Withdrawal of Prescription Drugs
JWatch Psychiatry 2002;2002:12-12.
FULL TEXT
Market Withdrawal of Prescription Drugs
JWatch General 2002;2002:9-9.
FULL TEXT
|
